Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Endocrinology and metabolism indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Metformin, sulfonylureas and pioglitazone

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Severe hypoglycaemia from a sulfonylurea can recur after initial correction and requires emergency assessment and prolonged monitoring. Severe dehydration, hypoxia, sepsis or acute kidney injury in a person taking metformin raises lactic-acidosis risk; stop the medicine and assess acid-base status and perfusion urgently.

Purpose and principles

Select and monitor established type 2 diabetes medicines by mechanism, kidney function, hypoglycaemia, heart failure, weight and adverse-effect risk.

These familiar agents differ profoundly. Metformin improves insulin sensitivity without driving insulin secretion; sulfonylureas stimulate secretion rapidly; pioglitazone changes nuclear transcription to improve peripheral sensitivity over weeks. Their speed, hypoglycaemia and organ effects should shape selection.

The central decision is not which tablet lowers HbA1c most, but which option complements cardiorenal-protective therapy and suits kidney function, heart failure, weight, frailty, pregnancy potential, occupation and willingness to monitor.

Combination therapy should be reviewed as a coherent regimen. When targets are not met, confirm diagnosis, adherence, lifestyle, steroid exposure and insulin deficiency before escalating, and remove drugs whose harm or burden now exceeds benefit.

Key points

  • Metformin reduces hepatic glucose production, is weight neutral or modestly weight reducing, and rarely causes hypoglycaemia alone; gastrointestinal intolerance and kidney function limit use.
  • Start metformin gradually with food and consider modified-release formulation when gastrointestinal effects prevent adherence; review renal thresholds against current BNF and NICE guidance.

Indications, selection and cautions

Metformin intolerance

Dose-related nausea, diarrhoea, abdominal discomfort or metallic taste often appears during rapid titration. Taking with food, slower increments or modified release may restore tolerability.

Metformin-associated risk stateRed flag

Acute kidney injury, severe dehydration, tissue hypoxia, sepsis or hepatic failure reduces lactate clearance and should trigger temporary withdrawal and urgent physiological assessment.

Vitamin B12 deficiency

Macrocytosis, anaemia, glossitis, fatigue, neuropathy, gait change or cognitive symptoms during longer-term metformin treatment needs testing; diabetic neuropathy should not be assumed automatically.

Sulfonylurea hypoglycaemiaRed flag

Sweating, tremor, confusion, focal neurology, seizure or coma may recur because drug action outlasts oral glucose, particularly in older adults and renal impairment.

Pioglitazone fluid retentionRed flag

New oedema, rapid weight gain, orthopnoea or breathlessness suggests fluid retention or heart failure and requires prompt medicine cessation and cardiac assessment.

Bladder warning

Visible or unexplained microscopic haematuria, dysuria or bladder-cancer history makes pioglitazone unsuitable until urological assessment resolves the concern.

Insulin deficiencyRed flag

Weight loss, ketosis, catabolic symptoms or very high symptomatic glucose despite tablets suggests marked beta-cell failure or misclassified diabetes and needs urgent insulin-capable review.

Assessment before treatment

  1. 01
    HbA1c and structured glucose dataFirst step
    Why
    Measure effect and detect excessive or inadequate treatment.
    Interpretation and limitations
    Expect metformin and pioglitazone effects over weeks to months; sulfonylurea acts sooner. Recurrent low readings outweigh a cosmetically favourable HbA1c and require de-intensification.
  2. 02
    eGFR and acute kidney assessment
    Why
    Determine metformin and sulfonylurea safety and dosing.
    Interpretation and limitations
    Apply current product-specific BNF thresholds and monitor more often as eGFR declines. An acute creatinine rise or dehydration is different from stable CKD and may require immediate temporary cessation.
  3. 03
    Vitamin B12 and full blood count
    Why
    Investigate neurological or haematological consequences of metformin.
    Interpretation and limitations
    Treat confirmed deficiency according to NICE guidance and usually continue metformin when otherwise suitable. Search for other causes rather than attributing every low level to the medicine.
  4. 04
    Weight, oedema and heart failure assessment
    Why
    Detect pioglitazone fluid retention and medicine-related weight change.

Treatment approach

01MetforminStart and maintain safelyFirst stepMetformin selected within the current NICE phenotype-based regimen.+
  1. 1Confirm kidney function, acute illness, alcohol exposure, tissue-hypoxia risk and pregnancy context; explain gastrointestinal effects and sick-day interruption before the first prescription.
  2. 2Start low with food and increase gradually using immediate or modified release according to tolerance and the current formulary, rather than beginning at the maximum dose.
  3. 3Review HbA1c and gastrointestinal burden, check eGFR at the required interval and investigate B12 when symptoms or risk factors arise.
  4. 4Temporarily stop during significant dehydration, acute kidney injury, hypoxia or protocol-defined contrast and perioperative situations, restarting after clinical and renal recovery is confirmed.
02SulfonylureaUse a secretagogue without avoidable harm

Regimens, contraindications and interactions

Lowers hepatic glucose output with little hypoglycaemia and usually no weight gain.

Metformin immediate or modified release

Start at a low dose with food and titrate using current renal guidance.

Check eGFR and acute illness, pause during severe dehydration or hypoxia, consider B12 monitoring, and follow current contrast and perioperative protocols. Gastrointestinal intolerance is dose related.

Provides relatively rapid insulin-secretagogue treatment for type 2 hyperglycaemia.

Gliclazide

Begin conservatively and titrate to glucose response under the local formulary.

Can cause prolonged hypoglycaemia and weight gain; adjust for renal or hepatic impairment, unreliable meals, frailty, driving and interacting medicines. Not a substitute for insulin in ketosis.

Improves peripheral insulin sensitivity without directly provoking hypoglycaemia when used alone.

Pioglitazone

Use the licensed once-daily dose and review response within three to six months.

Avoid in heart failure, bladder cancer or unexplained haematuria; monitor oedema, weight and fractures. Hypoglycaemia emerges when combined with insulin or secretagogues.

Complications, monitoring and follow-up

  • Check HbA1c at an interval that can show response and pair it with hypoglycaemia and symptom review; do not escalate several drugs before the first has had time to work.
  • Monitor eGFR at least to the frequency required by CKD stage and more often during intercurrent illness or after an acute kidney event.
  • Ask about gastrointestinal tolerance and B12 symptoms during metformin reviews, testing rather than labelling new neuropathy automatically as diabetic.
  • For sulfonylureas, review capillary lows, meal pattern, driving, falls, weight and renal function, with active de-intensification in frailty.
  • For pioglitazone, record weight, oedema, breathlessness, heart failure status, fractures and urinary blood, and document the three-to-six-month benefit decision.

Special situations

Modified release is not stronger

The formulation may improve gastrointestinal tolerability and adherence; it does not remove renal, hypoxia or B12 precautions and should not be described as a different mechanism.

Treat B12, keep useful metformin

Confirmed deficiency is corrected through the standard pathway and metformin can usually continue if still indicated. Stopping it alone does not address every competing cause.

Sulfonylurea lows recur

Food or intravenous glucose may correct the first reading while ongoing secretion drives another fall. Longer observation and specific emergency management may be required.

Oedema is a pharmacological signal

Pioglitazone-related fluid retention can precipitate heart failure, especially with insulin. New breathlessness or rapid weight gain warrants clinical assessment, not a diuretic added reflexively.

Old medicines still need review

Familiarity can breed automatic repeats. A clear indication, target, adverse-effect screen and stop rule are required just as for newer therapies.

Kidney function changes the hierarchy

Stable CKD may permit adjusted therapy, while an acute kidney injury requires temporary decisions. Use current product information rather than a remembered single eGFR number.

Common pitfalls

  1. 01

    Starting metformin at full dose and calling predictable gastrointestinal intolerance allergy.

  2. 02

    Missing vitamin B12 deficiency in a patient labelled with diabetic neuropathy.

  3. 03

    Using a sulfonylurea in someone with irregular meals and recurrent severe hypoglycaemia.

  4. 04

    Sending a sulfonylurea overdose home after one normal glucose reading.

  5. 05

    Prescribing pioglitazone despite heart failure or uninvestigated haematuria.

  6. 06

    Following a pre-2026 type 2 medicine ladder without checking current NICE guidance.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA

New oedema after pioglitazone

A person started pioglitazone two months ago and now has rapid weight gain, ankle oedema and orthopnoea. What is the most appropriate immediate medicine action?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Endocrinology and metabolism topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG28 type 2 diabetes recommendationsFebruary 2026 medicine selection and review.
  • BNF type 2 diabetes treatment summaryClass roles, contraindications and prescribing.
  • MHRA metformin vitamin B12 adviceRecognition and monitoring of B12 deficiency.
  • MHRA pioglitazone bladder cancer adviceContraindications and mandatory response review.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Metformin commonly lowers vitamin B12 over time, so investigate anaemia, neuropathy, glossitis or cognitive symptoms and consider periodic testing in those at risk.
  • Sulfonylureas increase pancreatic insulin release independent of current glucose and therefore cause hypoglycaemia and weight gain, especially with missed meals or reduced renal clearance.
  • Gliclazide is commonly used in the UK, but dose and suitability depend on renal and hepatic function, occupation, meal reliability and hypoglycaemia risk.
  • Pioglitazone improves insulin sensitivity but can cause fluid retention, weight gain and fractures; avoid in heart failure and active or previous bladder cancer or unexplained haematuria.
  • Review pioglitazone response and safety after several months and stop it when there is no meaningful benefit rather than continuing by inertia.
  • The February 2026 NICE type 2 algorithm is phenotype-led; do not reproduce an older step ladder from memory when choosing or combining these medicines.
  • All three classes need a sick-day or perioperative plan; insulin-deficient symptoms and marked hyperglycaemia should prompt insulin assessment instead of stacking tablets slowly.
    • Interpretation and limitations
    Examine jugular venous pressure and lungs and review natriuretic peptide or cardiac testing when clinically indicated. Oedema after initiation is not a benign marker of glycaemic response.
  • 05
    Urinalysis and haematuria pathway
    Why
    Identify a contraindication or warning before and during pioglitazone.
    Interpretation and limitations
    Uninvestigated blood in urine requires appropriate cancer-risk assessment; do not start or continue pioglitazone while assuming it is urinary infection without evidence.
  • 06
    Capillary glucose during illness or dose change
    Why
    Detect sulfonylurea hypoglycaemia and guide safe adjustments.
    Interpretation and limitations
    Increase testing after reduced intake, renal decline, exercise or interacting treatment. A long-acting secretagogue can cause recurrent lows even after food temporarily normalises glucose.
  • 07
    Ketones when catabolic or acutely unwell
    Why
    Identify insulin deficiency rather than endlessly escalating oral treatment.
    Interpretation and limitations
    Positive ketones with vomiting, dehydration or rapid breathing requires urgent hyperglycaemic-emergency assessment; metformin, sulfonylurea and pioglitazone do not treat DKA.
    • A rapid oral glucose-lowering effect is needed and hypoglycaemia risk is acceptable.
    +
    1. 1Assess renal and hepatic function, meal regularity, frailty, driving, occupational danger, previous hypoglycaemia and ability to monitor before choosing the agent and dose.
    2. 2Start conservatively and teach symptoms, measured treatment, repeat testing, delayed recurrence and when not to drive; review other insulin or secretagogue treatment concurrently.
    3. 3Reduce promptly with weight loss, poor intake, kidney decline or recurrent low readings and avoid using food supplementation to preserve an unnecessarily high dose.
    4. 4After severe or prolonged hypoglycaemia, arrange emergency observation and specialist toxicology or diabetes advice because recurrence can outlast the initial apparent recovery.
    03PioglitazoneSelect for insulin resistancePioglitazone is being considered after applying the current NICE medicine algorithm.+
    1. 1Exclude current or previous heart failure, active or previous bladder cancer, uninvestigated haematuria and important fracture risk; record baseline weight and oedema.
    2. 2Explain delayed onset, weight gain, fluid retention and fracture risk and choose the licensed dose through the current BNF and local formulary.
    3. 3Review glycaemic benefit and adverse effects after three to six months, stopping if there is no adequate response or if oedema, heart failure or haematuria develops.
    4. 4Reconsider need after major weight loss, insulin initiation, fracture or changing cardiovascular status rather than renewing indefinitely without benefit review.
    04FailureWhen tablets are not enoughPersistent symptomatic hyperglycaemia, catabolism or rising HbA1c despite an appropriate regimen.+
    1. 1Confirm the diabetes classification, medicine access and use, injection or monitoring needs, steroid exposure, infection and lifestyle barriers before adding another agent.
    2. 2Check glucose and ketones in symptomatic or weight-losing patients and arrange same-day insulin assessment when insulin deficiency is plausible.
    3. 3Use the February 2026 NICE comorbidity-led options, preserving indicated cardiorenal therapy and avoiding combinations whose mechanism or safety conflicts.
    4. 4Set a treatment target and review date for every addition, removing ineffective medicine and simplifying when burden or hypoglycaemia rises.